Boston Scientific Corp
BSXQ2 2022(BSX Q1 FY2022)Estimated1% AI
AI Revenue %
1%
AI Fair Value
$393.1M
AI Revenue (Q)
$30.3M
Total Revenue (Q)
$3.0B
Source: SEC EDGAR SEC Filing Filing
View SEC Filing on SEC.govAnalysis
BSX reported $3,026M in Q1 2022 net sales, entirely from MedSurg and Cardiovascular medical devices. No AI revenue segment or AI product disclosures; AI exposure limited to potential software algorithms embedded in digital endoscopy and imaging devices, representing a negligible fraction of total revenue.
Analyzed by claude-opus-4-6
Confidence Tier
EstimatedNo direct AI revenue disclosure — estimated from product mix